Method of screening for drug hypersensitivity reaction
Methods of assessing the risk of clinical signs of hypersensitivity reaction to nucleoside antiviral compounds, including abacavir, are described. The methods include genotyping subjects for polymorphisms in the TNFα gene, the class 1 HLA genes, or a combination of both the TNFα and HLA genes.
1. A method of identifying a male Caucasian human subject at increased risk of experiencing a hypersensitivity reaction to a therapeutic regime of abacavir, comprising:
(a) performing a genotyping technique on a biological sample from said subject to determine whether the subject's HLA-B genotype includes an allele selected from the HLA-B57 allele and the HLA-B*5701 allele;
(b) detecting an HLA-B57 allele or an HLA-B*5701 allele; and
(c) correlating the detection of an HLA-B57 or an HLA-B*5701 allele with an increased risk of experiencing a hypersensitivity reaction to a therapeutic regime of abacavir compared to the risk if no HLA-B57 or HLA-B*5701 allele were detected.
2. A method according to claim 1 , where said subject has not previously been treated with abacavir.
3. A method according to claim 1 , where said subject has previously been treated with abacavir.
4. A method according to claim 1 , where one or two copies of the HLA-B57 allele is detected.
5. A method according to claim 1 , further comprising determining the presence of a polymorphism in the TNFα gene, where said TNFα polymorphism has been associated with an increased risk of abacavir hypersensitivity reaction.
6. A method according to claim 1 where said HLA genotype is determined by a method that detects the presence of the allelic DNA sequence.
7. A method according to claim 1 where said subject is infected with the Human Immunodeficiency Virus-1 (HIV-1).
8. A method according to claim 1 , where an HLA-B*5701 allele is detected.
9. A method of identifying a male Caucasian human subject at increased risk of experiencing a hypersensitivity reaction to a therapeutic regime of abacavir, comprising:
(a) performing a genotyping technique on a biological sample from said subject to determine whether the subject's HLA-B genotype includes an allele selected from the HLA-B57 allele and the HLA-B*5701 allele;
(b) detecting an HLA-B57 allele or an HLA-B*5701 allele; and
(c) identifying said subject as at increased risk of experiencing a hypersensitivity reaction to a therapeutic regime of abacavir compared to the risk if no HLA-B57 or HLA-B*5701 allele were detected.
10. A method according to claim 9 , where said subject has not previously been treated with abacavir.
11. A method according to claim 9 , where said subject has previously been treated with abacavir.
12. A method according to claim 9 , where one or two copies of the HLA-B57 allele is detected.
13. A method according to claim 9 , further comprising determining the presence of a polymorphism in the TNFα gene, where said TNFα polymorphism has been associated with an increased risk of abacavir hypersensitivity reaction.
14. A method according to claim 9 where said HLA genotype is determined by a method that detects the presence of the allelic DNA sequence.
15. A method according to claim 9 where said subject is infected with the Human Immunodeficiency Virus-1 (HIV-1).
16. A method according to claim 1 , where an HLA-B*5701 allele is detected.
17. A method according to claim 1 , wherein said biological sample is selected from the group consisting of cells, blood, blood components, urine and saliva.
18. A method according to claim 9 , wherein said biological sample is selected from the group consisting of cells, blood, blood components, urine and saliva.